Key information
- Cerebrospinal fluid biomarkers for Alzheimer’s and Parkinson’s disease and their application in clinical trials
Professional Details
Centro Médico Teknon
SPECIALIST PHYSICIAN NEUROLOGY
May 2021 -
Present
Hospital de Sant Jaume
Specialist doctor
January 2005 - January 2008
Hospital Gral. de Almansa
Training Period
January 2002 - January 2005
Study
Bachelor of Medicine and Surgery
university, Universidad de Barcelona
1995
Doctorate
Universidad de Barcelona
2002
Specialized Healthcare Training
Neurology Specialist
hospital
Universidad Autónoma de Barcelona
Cerebrospinal fluid biomarkers for Alzheimer’s and Parkinson’s disease and their application in clinical trials
Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimers Disease Cerebrospinal Fluid
Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimers disease continuum in the BIOMARKAPD study
Nonsteroidal anti-inflammatory drugs lower Ab42 and change presenilin 1 conformation
Make an appointment with this professional


































